Amylin Pharmaceuticals and Lilly have entered into a product supply agreement for exenatide once weekly, a compound under development to treat type 2 diabetes. Under terms of the agreement, Amylin will receive an initial cash payment of $125 million and Amylin will supply product for sales in the U.S. and to Lilly for sales outside of the U.S. Lilly will also reimburse Amylin for its share of the $500-plus million capital investment in the West Chester, OH facility through the cost of goods sold...